MYGN
NASDAQ · Biotechnology
Myriad Genetics Inc
$4.27
+0.18 (+4.40%)
Open$4.10
Previous Close$4.09
Day High$4.29
Day Low$4.00
52W High$8.59
52W Low$3.75
Volume—
Avg Volume1.93M
Market Cap379.68M
P/E Ratio—
EPS$-3.95
SectorBiotechnology
Analyst Ratings
Sell
18 analysts
Price Target
+870.5% upside
Current
$4.27
$4.27
Target
$41.44
$41.44
$29.39
$41.44 avg
$63.29
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 791.72M | 741.87M | 74.53M |
| Net Income | -351,352,398 | -296,305,433 | -15,758,896 |
| Profit Margin | -44.4% | -42.2% | -21.1% |
| EBITDA | -319,475,131 | -284,390,343 | -16,042,014 |
| Free Cash Flow | — | — | -13,316,178 |
| Rev Growth | +6.7% | +6.7% | +5.3% |
| Debt/Equity | 0.33 | 0.33 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |